Revelation Biosciences Q3 net loss $1.9M, cash $12.7M; cash runway through Q3 2026

REVELATION BIOSCIENCES, INC.

2025-Q3 EPS reported -$9.76

Net loss for Q3 2025 was $1.9M ($1.77 per share) vs $2.2M ($40.15) in Q3 2024.
Cash and equivalents $12.7M at Sept 30, 2025, up from $6.5M at Dec 31, 2024.
Received $9.6M gross proceeds from warrant inducement in September 2025.
Announced top-line results from PRIME clinical study; plans FDA meeting for Gemini registration path.
Net cash used in operations $6.3M for 9 months 2025 vs $14.6M in same period 2024.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.